Baudax Bio

Baudax Bio, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for acute care settings. The company was founded in 2015 and is headquartered in Malvern, PA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Company Also Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Baudax Bio Strengthens Management Team with Appointment of Richard S. Casten as Chief Financial Officer

MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, President and Chief Executive Officer, will give a corporate presentation at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

Baudax Bio to Present at the H.C. Wainwright Global Life Sciences Conference

Investors need to pay close attention to Baudax Bio (BXRX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Baudax Bio (BXRX) Stock?

Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q4 2020 Results - Earnings Call Transcript

MALVERN, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced that it will report full year 2020 financial results on Tuesday, February 16, 2021. Baudax's management team will host a conference call and webcast at 8:00 a.m. ET on Tuesday, February 16, 2021 to discuss the financial results and recent operational highlights.

Baudax Bio to Report 2020 Annual Financial Results and Host Conference Call and Webcast on February 16, 2021

MALVERN, Pa., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced that it has entered into a definitive agreement with institutional and accredited investors for the purchase and sale of an aggregate of 11,000,000 shares of common stock at a purchase price of $1.60 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 10, 2021, subject to the satisfaction of customary closing conditions.

Baudax Bio Announces $17.6 Million Offering Priced At-the-Market under Nasdaq Rules

Baudax (BXRX) will provide updates on earnings and revenues when it releases results for fourth-quarter 2020.

Baudax (BXRX) to Report Q4 Earnings: What's in the Cards?

MALVERN, Pa., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the agreement by an accredited healthcare-focused institutional investor to cash exercise certain warrants to purchase up to an aggregate of 10,300,430 shares of common stock having an exercise price of $1.18 issued by the company in December 2020. The shares of common stock issuable upon exercise of the warrants are registered pursuant to a registration statement on Form S-3 (File No. 333-243488). In consideration for the immediate exercise of the warrants for cash, the company will sell to the exercising holder an additional warrant pursuant to the registration statement. The new warrant will be cash exercisable for an aggregate of up to 10,300,430 shares of common stock at an exercise price of $1.60 per share and have a term of exercise equal to five years. The purchase price of the additional warrant will be $1,287,553.75, or $0.125 per warrant share.

Baudax Bio Announces Exercise of Warrants for Gross Proceeds of $13.4 Million

MALVERN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, (“Baudax Bio” or the “Company”) today announced that it has entered into a definitive agreement with a healthcare-focused institutional investor for the purchase and sale of an aggregate of 10,300,430 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to an aggregate of 10,300,430 shares of common stock at a purchase price of $1.165 per share (or $1.155 per prefunded warrant) and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The warrants have an exercise price of $1.18 per share, are exercisable immediately, and will expire five years following the date of issuance. The closing of the offering is expected to occur on or about December 21, 2020, subject to the satisfaction of customary closing conditions.

Baudax Bio Announces $12 Million Offering Priced at a Premium to Market

Implied Volatility Surging for Baudax Bio (BXRX) Stock Options

MALVERN, Pa., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference, being held virtually December 1-3, 2020. The company will conduct institutional investor meetings on December 2, 2020; meetings may be requested through Piper Sandler.

Baudax Bio to Participate in the Piper Sandler 32nd Annual Healthcare Conference

ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety Compared to Other Approved IV Non-Opioid Analgesics ANJESO Found to Provide Superior Pain Relief with Similar or Better Safety Compared to Other Approved IV Non-Opioid Analgesics

Baudax Bio Announces Publication of ANJESO® Network Meta-Analysis in the Peer-Reviewed Journal BMC Anesthesiology

Baudax Bio, Inc. (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript

Baudax Bio, Inc.'s (BXRX) CEO Gerri Henwood on Q3 2020 Results - Earnings Call Transcript

BXRX has been pummeled since the start of the pandemic dropping from the high $7s to the low $1s. In this article, I review the company developments, both negative and positive, that have transpired during the period.

Baudax Bio: Why I'm Catching This Falling Knife

MALVERN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it will report third quarter 2020 financial results on Monday, November 9, 2020. Baudax's management team will host a conference call and audio webcast at 9:00 a.m. ET on Monday, November 9, 2020 to discuss the financial results and recent operational highlights.

Baudax Bio to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020

ANJESO ® Launch Underway ; Over 50 Institutions have A dded ANJESO to T heir F ormular ies

Baudax Bio Provides Commercial and Corporate Update

MALVERN, Pa., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 24,000 shares of Baudax Bio’s common stock and restricted stock units covering 6,000 shares of Baudax Bio’s common stock to 3 newly-hired employees, with a grant date of September 30, 2020. The equity awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation and were granted as an inducement material to his or her acceptance of employment with Baudax Bio.

Baudax Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MALVERN, Pa., Sept.  18, 2020  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on Tuesday, September 22, 2020 at 3:20 p.m. ET.

Baudax Bio to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit

Amyris

aTyr Pharma

These penny stocks are company names that won’t break the bank, and boast colossal growth prospects for the 12 months ahead.
The post 3 Penny Stocks That Have Triple-Digit Upside Potential appeared first on InvestorPlace.

3 Penny Stocks That Have Triple-Digit Upside Potential

Baudax Bio: Discounted Despite Long-Term Prospects

MALVERN, Pa., Aug.  25, 2020  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has been awarded a Group Purchasing Agreement with Premier Inc.  Effective August 2020, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for ANJESO (meloxicam) injection, for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics.

Baudax Bio Awarded Group Purchasing Agreement with Premier Inc. for ANJESO®

MALVERN, Pa., Aug.  20, 2020  (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced that Arnold Baskies, M.D. and Andrew Drechsler, have been appointed to the Company's Board of Directors.

Baudax Bio Appoints Arnold Baskies, M.D. and Andrew Drechsler to Board of Directors

Baudax Bio's (BXRX) CEO Gerri Henwood on Q2 2020 Results - Earnings Call Transcript

Commenced Commercial Launch of ANJESO ® in the U.S.

News for Baudax Bio Stock (BXRX)